Dose Finding in Drug Development

If you have ever wondered when visiting the pharmacy how the dosage of your prescription is determined this book will answer your questions. Dosing information on drug labels is based on discussion between the pharmaceutical manufacturer and the drug regulatory agency, and the label is a summary of results obtained from many scientific experiments. The book introduces the drug development process, the design and the analysis of clinical trials. Many of the discussions are based on applications of statistical methods in the design and analysis of dose response studies. Important procedural steps from a pharmaceutical industry perspective are also examined.

[1]  L. Goodman,et al.  The Pharmacological Basis of Therapeutics , 1941 .

[2]  Georg v. Békésy,et al.  A New Audiometer , 1947 .

[3]  Alexander M. Mood,et al.  A Method for Obtaining and Analyzing Sensitivity Data , 1948 .

[4]  N. Metropolis,et al.  Equation of State Calculations by Fast Computing Machines , 1953, Resonance.

[5]  S. N. Roy.  On a Heuristic Method of Test Construction and its use in Multivariate Analysis , 1953 .

[6]  E. C. Fieller.  SOME PROBLEMS IN INTERVAL ESTIMATION , 1954 .

[7]  E Blacker.  Some design considerations , 1960 .

[8]  John W. Tukey,et al.  Efficient Utilization of Non-Numerical Information in Quantitative Analysis General Theory and the Case of Simple Order , 1963 .

[9]  D. A. Mcquarrie.  Stochastic approach to chemical kinetics , 1967, Journal of Applied Probability.

[10]  Asymptotic Properties of the Block Up-and-Down Method in Bio-assay , 1967 .

[11]  G. Segre,et al.  Kinetics of interaction between drugs and biological systems. , 1968, Il Farmaco; edizione scientifica.

[12]  G. Levy,et al.  Kinetics of pharmacologic effects in man: The anticoagulant action of warfarin , 1969, Clinical pharmacology and therapeutics.

[13]  W. K. Hastings,et al.  Monte Carlo Sampling Methods Using Markov Chains and Their Applications , 1970 .

[14]  D. Rall,et al.  The evaluation of anticancer drugs in dogs and monkeys for the prediction of qualitative toxicities in man , 1970, Clinical pharmacology and therapeutics.

[15]  Williams Da,et al.  A test for differences between treatment means when several dose levels are compared with a zero dose control. , 1971 .

[16]  Williams Da,et al.  The comparison of several dose levels with a zero dose control. , 1972 .

[17]  Robert K. Tsutakawa,et al.  Design of Experiment for Bioassay , 1972 .

[18]  S. Zacks,et al.  Sequential Search of an Optimal Dosage, I , 1973 .

[19]  H. Akaike,et al.  Information Theory and an Extension of the Maximum Likelihood Principle , 1973 .

[20]  K. Gabriel,et al.  On closed testing procedures with special reference to ordered analysis of variance , 1976 .

[21]  Lewis B. Sheiner,et al.  Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d‐tubocurarine , 1979 .

[22]  R. Tsutakawa.  Selection of Dose Levels for Estimating a Percentage Point of a Logistic Quantal Response Curve , 1980 .

[23]  L. Sheiner,et al.  Understanding the Dose-Effect Relationship , 1981, Clinical pharmacokinetics.

[24]  Norman R. Draper,et al.  Applied regression analysis (2. ed.) , 1981, Wiley series in probability and mathematical statistics.

[25]  R. Vaidya,et al.  Initial human trials with an investigational new drug (phase I and 2): planning an management. , 1981, Journal of postgraduate medicine.

[26]  R. Temple,et al.  Government Viewpoint of Clinical Trials , 1982 .

[27]  J A Hanley,et al.  If nothing goes wrong, is everything all right? Interpreting zero numerators. , 1983, JAMA.

[28]  J W Tukey,et al.  Testing the statistical certainty of a response to increasing doses of a drug. , 1985, Biometrics.

[29]  David Salsburg,et al.  Statistics for toxicologists , 1986 .

[30]  F. T. Wright,et al.  Order restricted statistical inference , 1988 .

[31]  Douglas M. Bates,et al.  Nonlinear Regression Analysis and Its Applications , 1988 .

[32]  L. Sheiner,et al.  Study designs for dose‐ranging , 1989, Clinical pharmacology and therapeutics.

[33]  Stephen J. Ruberg,et al.  Contrasts for Identifying the Minimum Effective Dose , 1989 .

[34]  B E Storer,et al.  Design and analysis of phase I clinical trials. , 1989, Biometrics.

[35]  G. Decoster,et al.  Responses and toxic deaths in phase I clinical trials. , 1990, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  J O'Quigley,et al.  Continual reassessment method: a practical design for phase 1 clinical trials in cancer. , 1990, Biometrics.

[37]  L B Sheiner,et al.  A simulation study comparing designs for dose ranging. , 1991, Statistics in medicine.

[38]  Trevor Hastie,et al.  Statistical Models in S , 1991 .

[39]  B. Spilker.  Guide to clinical trials , 1991 .

[40]  N. Holford.  PHYSIOLOGICAL ALTERNATIVES TO THE EFFECT COMPARTMENT MODEL , 1991 .

[41]  J B Greenhouse,et al.  Bayesian methods for phase I clinical trials. , 1992, Statistics in medicine.

[42]  P. Workman,et al.  The impact of pharmacokinetically guided dose escalation strategies in phase I clinical trials: critical evaluation and recommendations for future studies. , 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

[43]  D R Stanski,et al.  Pharmacodynamic modeling of anesthetic EEG drug effects. , 1992, Annual review of pharmacology and toxicology.

[44]  M J Ratain,et al.  Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. , 1993, Journal of the National Cancer Institute.

[45]  F. Pukelsheim.  Optimal Design of Experiments , 1993 .

[46]  L V Rubinstein,et al.  A comparison of two phase I trial designs. , 1994, Statistics in medicine.

[47]  S. T. Buckland,et al.  Computer Intensive Statistical Methods: Validation, Model Selection, and Bootstrap , 1993 .

[48]  H Boxenbaum,et al.  First‐Time‐in‐Human Dose Selection: Allometric Thoughts and Perspectives , 1995, Journal of clinical pharmacology.

[49]  David Draper,et al.  Assessment and Propagation of Model Uncertainty , 2011 .

[50]  J Whitehead,et al.  Bayesian decision procedures for dose determining experiments. , 1995, Statistics in medicine.

[51]  Hepatotoxicity of antiviral agents. , 1995, Gastroenterology clinics of North America.

[52]  L. Skovgaard.  NONLINEAR MODELS FOR REPEATED MEASUREMENT DATA. , 1996 .

[53]  Weng Kee Wong,et al.  Designing Studies for Dose Response , 1996 .

[54]  J. Hsu.  Multiple Comparisons: Theory and Methods , 1996 .

[55]  E. Vonesh,et al.  Linear and Nonlinear Models for the Analysis of Repeated Measurements , 1996 .

[56]  K. Burnham,et al.  Model selection: An integral part of inference , 1997 .

[57]  R. Christopher Pierce,et al.  A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants , 1997, Brain Research Reviews.

[58]  Stephen Senn,et al.  Statistical Issues in Drug Development , 1997 .

[59]  P. O'Byrne,et al.  Prolonged protection against exercise-induced bronchoconstriction by the leukotriene D4-receptor antagonist cinalukast. , 1997, The Journal of allergy and clinical immunology.

[60]  S Zacks,et al.  Cancer phase I clinical trials: efficient dose escalation with overdose control. , 1998, Statistics in medicine.

[61]  L. Wojnar.  Analysis and interpretation , 1998 .

[62]  Ethan Reiner,et al.  Operating characteristics of the standard phase I clinical trial design , 1999 .

[63]  Lynne Milgram,et al.  Law of Diminishing Returns , 1999 .

[64]  I Mahmood,et al.  The Pharmacokinetic Principles Behind Scaling from Preclinical Results to Phase I Protocols , 1999, Clinical pharmacokinetics.

[65]  J O'Quigley,et al.  Two-sample continual reassessment method. , 1999, Journal of biopharmaceutical statistics.

[66]  Kazuo Anraku,et al.  An information criterion for parameters under a simple order restriction , 1999 .

[67]  S. Ellenberg,et al.  Placebo-Controlled Trials and Active-Control Trials in the Evaluation of New Treatments. Part 2: Practical Issues and Specific Cases , 2000, Annals of Internal Medicine.

[68]  L B Sheiner,et al.  Pharmacokinetic/pharmacodynamic modeling in drug development. , 2000, Annual review of pharmacology and toxicology.

[69]  S. Ruberg,et al.  Detecting dose response with contrasts. , 2000, Statistics in medicine.

[70]  M. Karlsson,et al.  Models of schedule dependent haematological toxicity of 2'-deoxy-2'-methylidenecytidine (DMDC) , 2000, European Journal of Clinical Pharmacology.

[71]  N H Holford,et al.  Simulation of clinical trials. , 2000, Annual review of pharmacology and toxicology.

[72]  C. Peck,et al.  Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic model , 2000, Clinical pharmacology and therapeutics.

[73]  D. Bates,et al.  Mixed-Effects Models in S and S-PLUS , 2001 .

[74]  Trevor Hastie,et al.  The Elements of Statistical Learning , 2001 .

[75]  K. Blesch,et al.  Estimating the starting dose for entry into humans: principles and practice , 2002, European Journal of Clinical Pharmacology.

[76]  M. Boroujerdi.  Pharmacokinetics : Principles and Applications , 2001 .

[77]  Charles W. Dunnett,et al.  Multiple Test Procedures for Identifying the Maximum Safe Dose , 2001 .

[78]  N H Holford,et al.  Drug treatment effects on disease progression. , 2001, Annual review of pharmacology and toxicology.

[79]  L. Lesko,et al.  Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. , 2001, Annual review of pharmacology and toxicology.

[80]  Martin Posch,et al.  Multiple Testing for Identifying Effective and Safe Treatments , 2001 .

[81]  B. Penninx,et al.  Evaluation and Correction for a ‘Training Effect’ in the Cognitive Assessment of Older Adults , 2002, Neuroepidemiology.

[82]  Elisa Guerrero Vázquez,et al.  Multiple comparison procedures applied to model selection , 2002, Neurocomputing.

[83]  Richard W. Lewis,et al.  Recognition of Adverse and Nonadverse Effects in Toxicity Studies , 2002, Toxicologic pathology.

[84]  S. Jan,et al.  NONPARAMETRIC IDENTIFICATION OF THE MINIMUM EFFECTIVE DOSE FOR RANDOMIZED BLOCK DESIGNS , 2002 .

[85]  Joy A. Cavagnaro,et al.  Preclinical safety evaluation of biotechnology-derived pharmaceuticals , 2002, Nature Reviews Drug Discovery.

[86]  William F Rosenberger,et al.  Competing designs for phase I clinical trials: a review , 2002, Statistics in medicine.

[87]  Frank Bretz,et al.  Comparison of Methods for the Computation of Multivariate t Probabilities , 2002 .

[88]  N. White,et al.  Oral Artesunate Dose-Response Relationship in Acute Falciparum Malaria , 2002, Antimicrobial Agents and Chemotherapy.

[89]  Naitee Ting,et al.  Dose Spacing in Early Dose Response Clinical Trial Designs , 2002 .

[90]  Thomas Ludden,et al.  Randomized concentration‐controlled trials: Motivations, use, and limitations , 2003, Clinical pharmacology and therapeutics.

[91]  L. Haines,et al.  Bayesian Optimal Designs for Phase I Clinical Trials , 2003, Biometrics.

[92]  L. Natarajan,et al.  Interval estimates of the probability of toxicity at the maximum tolerated dose for small samples , 2003, Statistics in medicine.

[93]  D. Dieterich,et al.  Hepatotoxicity of antiretroviral therapy. , 2003, AIDS reviews.

[94]  Stephen B. Duffull,et al.  Simulations for Designing Clinical Trials , 2003 .

[95]  John O'Quigley,et al.  Continual Reassessment Method for Ordered Groups , 2003, Biometrics.

[96]  S. Holm,et al.  Evaluation of the Cohort Size in Phase I Dose Escalation Trials Based on Laboratory Data , 2003, Journal of clinical pharmacology.

[97]  L. Lesko,et al.  Use of biomarkers from drug discovery through clinical practice: Report of the Ninth European Federation of Pharmaceutical Sciences Conference on Optimizing Drug Development , 2003, Clinical pharmacology and therapeutics.

[98]  Anastasia Ivanova,et al.  Improved up‐and‐down designs for phase I trials , 2003, Statistics in medicine.

[99]  Jack A. Cook,et al.  The Use of Clinical Trial Simulation to Support Dose Selection: Application to Development of a New Treatment for Chronic Neuropathic Pain , 2003, Pharmaceutical Research.

[100]  N. Lazar,et al.  Methods and Criteria for Model Selection , 2004 .

[101]  Peter L. Bonate,et al.  Clinical Trial Simulation in Drug Development , 2000, Pharmaceutical Research.

[102]  Roberto Gomeni,et al.  In Silico Prediction of Optimal in Vivo Delivery Properties Using Convolution-Based Model and Clinical Trial Simulation , 2004, Pharmaceutical Research.

[103]  E. Gragoudas,et al.  Pegaptanib for neovascular age-related macular degeneration. , 2004, The New England journal of medicine.

[104]  Xiaotong Shen,et al.  Inference After Model Selection , 2004 .

[105]  Timothy Goggin,et al.  A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis. , 2004, British journal of clinical pharmacology.

[106]  K. Peace,et al.  The effect of tacrine and lecithin in Alzheimer's disease , 2004, European Journal of Clinical Pharmacology.

[107]  C. Tanner,et al.  Levodopa and the progression of Parkinson's disease. , 2004, The New England journal of medicine.

[108]  Stephen M Stahl,et al.  The many faces of fatigue in major depressive disorder. , 2005, The international journal of neuropsychopharmacology.

[109]  F Bretz,et al.  Combining Multiple Comparisons and Modeling Techniques in Dose‐Response Studies , 2005, Biometrics.

[110]  J. Babb,et al.  Flexible Bayesian methods for cancer phase I clinical trials. Dose escalation with overdose control , 2005, Statistics in medicine.

[111]  P. Nicoletti,et al.  Novel therapeutic targets , 2006, Neurological Sciences.

[112]  David J. Spiegelhalter,et al.  Estimation of population pharmacokinetics using the Gibbs sampler , 1995, Journal of Pharmacokinetics and Biopharmaceutics.

[113]  J. Macdougall.  Analysis of Dose–Response Studies—E max Model , 2006 .